Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules
The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for ex...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Westendorf, Astrid M. [verfasserIn] Gunzer, Florian [verfasserIn] Deppenmeier, Stefanie [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 2005 |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2006 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: FEMS immunology and medical microbiology - Federation of European Microbiological Societies ; GKD-ID: 114439X, Oxford [u.a.] : Wiley-Blackwell, 1993, 43(2005), 3, Seite 0 |
| Übergeordnetes Werk: |
volume:43 ; year:2005 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.femsim.2004.10.023 |
|---|
| Katalog-ID: |
NLEJ242923313 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242923313 | ||
| 003 | DE-627 | ||
| 005 | 20230505190905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1016/j.femsim.2004.10.023 |2 doi | |
| 035 | |a (DE-627)NLEJ242923313 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Westendorf, Astrid M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 2005 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. | ||
| 533 | |d 2006 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2006|||||||||| | ||
| 700 | 1 | |a Gunzer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Deppenmeier, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Tapadar, Damini |4 oth | |
| 700 | 1 | |a Hunger, J. Katrin |4 oth | |
| 700 | 1 | |a Schmidt, M. Alexander |4 oth | |
| 700 | 1 | |a Buer, Jan |4 oth | |
| 700 | 1 | |a Bruder, Dunja |4 oth | |
| 773 | 0 | 8 | |i In |a Federation of European Microbiological Societies ; GKD-ID: 114439X |t FEMS immunology and medical microbiology |d Oxford [u.a.] : Wiley-Blackwell, 1993 |g 43(2005), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926014 |w (DE-600)1500464-8 |x 1574-695X |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2005 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.femsim.2004.10.023 |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2005 |e 3 |h 0 | ||
| author_variant |
a m w am amw f g fg s d sd |
|---|---|
| matchkey_str |
article:1574695X:2005----::netnlmuiyfshrciclnsl11aaearefr |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1016/j.femsim.2004.10.023 doi (DE-627)NLEJ242923313 DE-627 ger DE-627 rakwb Westendorf, Astrid M. verfasserin aut Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Gunzer, Florian verfasserin aut Deppenmeier, Stefanie verfasserin aut Tapadar, Damini oth Hunger, J. Katrin oth Schmidt, M. Alexander oth Buer, Jan oth Bruder, Dunja oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 43(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:43 year:2005 number:3 pages:0 http://dx.doi.org/10.1016/j.femsim.2004.10.023 text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 43 2005 3 0 |
| spelling |
10.1016/j.femsim.2004.10.023 doi (DE-627)NLEJ242923313 DE-627 ger DE-627 rakwb Westendorf, Astrid M. verfasserin aut Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Gunzer, Florian verfasserin aut Deppenmeier, Stefanie verfasserin aut Tapadar, Damini oth Hunger, J. Katrin oth Schmidt, M. Alexander oth Buer, Jan oth Bruder, Dunja oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 43(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:43 year:2005 number:3 pages:0 http://dx.doi.org/10.1016/j.femsim.2004.10.023 text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 43 2005 3 0 |
| allfields_unstemmed |
10.1016/j.femsim.2004.10.023 doi (DE-627)NLEJ242923313 DE-627 ger DE-627 rakwb Westendorf, Astrid M. verfasserin aut Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Gunzer, Florian verfasserin aut Deppenmeier, Stefanie verfasserin aut Tapadar, Damini oth Hunger, J. Katrin oth Schmidt, M. Alexander oth Buer, Jan oth Bruder, Dunja oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 43(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:43 year:2005 number:3 pages:0 http://dx.doi.org/10.1016/j.femsim.2004.10.023 text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 43 2005 3 0 |
| allfieldsGer |
10.1016/j.femsim.2004.10.023 doi (DE-627)NLEJ242923313 DE-627 ger DE-627 rakwb Westendorf, Astrid M. verfasserin aut Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Gunzer, Florian verfasserin aut Deppenmeier, Stefanie verfasserin aut Tapadar, Damini oth Hunger, J. Katrin oth Schmidt, M. Alexander oth Buer, Jan oth Bruder, Dunja oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 43(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:43 year:2005 number:3 pages:0 http://dx.doi.org/10.1016/j.femsim.2004.10.023 text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 43 2005 3 0 |
| allfieldsSound |
10.1016/j.femsim.2004.10.023 doi (DE-627)NLEJ242923313 DE-627 ger DE-627 rakwb Westendorf, Astrid M. verfasserin aut Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Gunzer, Florian verfasserin aut Deppenmeier, Stefanie verfasserin aut Tapadar, Damini oth Hunger, J. Katrin oth Schmidt, M. Alexander oth Buer, Jan oth Bruder, Dunja oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 43(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:43 year:2005 number:3 pages:0 http://dx.doi.org/10.1016/j.femsim.2004.10.023 text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 43 2005 3 0 |
| source |
In FEMS immunology and medical microbiology 43(2005), 3, Seite 0 volume:43 year:2005 number:3 pages:0 |
| sourceStr |
In FEMS immunology and medical microbiology 43(2005), 3, Seite 0 volume:43 year:2005 number:3 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
FEMS immunology and medical microbiology |
| authorswithroles_txt_mv |
Westendorf, Astrid M. @@aut@@ Gunzer, Florian @@aut@@ Deppenmeier, Stefanie @@aut@@ Tapadar, Damini @@oth@@ Hunger, J. Katrin @@oth@@ Schmidt, M. Alexander @@oth@@ Buer, Jan @@oth@@ Bruder, Dunja @@oth@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926014 |
| id |
NLEJ242923313 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242923313</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505190905.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.femsim.2004.10.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242923313</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Westendorf, Astrid M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2006</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2006||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunzer, Florian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deppenmeier, Stefanie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tapadar, Damini</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hunger, J. Katrin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, M. Alexander</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buer, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bruder, Dunja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="a">Federation of European Microbiological Societies ; GKD-ID: 114439X</subfield><subfield code="t">FEMS immunology and medical microbiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1993</subfield><subfield code="g">43(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926014</subfield><subfield code="w">(DE-600)1500464-8</subfield><subfield code="x">1574-695X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:43</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1016/j.femsim.2004.10.023</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">43</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Westendorf, Astrid M. |
| spellingShingle |
Westendorf, Astrid M. Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| authorStr |
Westendorf, Astrid M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926014 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1574-695X |
| topic_title |
Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d t dt j k h jk jkh m a s ma mas j b jb d b db |
| hierarchy_parent_title |
FEMS immunology and medical microbiology |
| hierarchy_parent_id |
NLEJ243926014 |
| hierarchy_top_title |
FEMS immunology and medical microbiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926014 (DE-600)1500464-8 |
| title |
Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| ctrlnum |
(DE-627)NLEJ242923313 |
| title_full |
Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| author_sort |
Westendorf, Astrid M. |
| journal |
FEMS immunology and medical microbiology |
| journalStr |
FEMS immunology and medical microbiology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Westendorf, Astrid M. Gunzer, Florian Deppenmeier, Stefanie |
| container_volume |
43 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Westendorf, Astrid M. |
| doi_str_mv |
10.1016/j.femsim.2004.10.023 |
| author2-role |
verfasserin |
| title_sort |
intestinal immunity of escherichia coli nissle 1917: a safe carrier for therapeutic molecules |
| title_auth |
Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| abstract |
The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. |
| abstractGer |
The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. |
| abstract_unstemmed |
The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
3 |
| title_short |
Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules |
| url |
http://dx.doi.org/10.1016/j.femsim.2004.10.023 |
| remote_bool |
true |
| author2 |
Gunzer, Florian Deppenmeier, Stefanie Tapadar, Damini Hunger, J. Katrin Schmidt, M. Alexander Buer, Jan Bruder, Dunja |
| author2Str |
Gunzer, Florian Deppenmeier, Stefanie Tapadar, Damini Hunger, J. Katrin Schmidt, M. Alexander Buer, Jan Bruder, Dunja |
| ppnlink |
NLEJ243926014 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.femsim.2004.10.023 |
| up_date |
2024-07-06T03:41:07.510Z |
| _version_ |
1803799513017614337 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242923313</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505190905.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.femsim.2004.10.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242923313</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Westendorf, Astrid M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2006</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2006||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunzer, Florian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deppenmeier, Stefanie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tapadar, Damini</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hunger, J. Katrin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, M. Alexander</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buer, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bruder, Dunja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="a">Federation of European Microbiological Societies ; GKD-ID: 114439X</subfield><subfield code="t">FEMS immunology and medical microbiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1993</subfield><subfield code="g">43(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926014</subfield><subfield code="w">(DE-600)1500464-8</subfield><subfield code="x">1574-695X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:43</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1016/j.femsim.2004.10.023</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">43</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.402011 |